'The Top Line': The financial trends biotechs could face in 2023, plus this week's headlines

2022 was a tough year for biotechs in anyone’s book. At Fierce, we recorded 119 companies that resorted to laying off staff. And judging by the Fierce Biotech Layoff Tracker, 2023 is looking like more of the same. Fierce Biotech’s James Waldron sat down with Glenn Hunzinger, the U.S. pharma and life science leader at PwC, to talk about the financial trends he expects biotechs to face in 2023. 

Plus, in this episode, we cover Emergent's Narcan over-the-counter approval, the first PTSD neuromodulation device approval and more of this week's top headlines. 


To learn more about the topics in this episode: 

The Top Line is produced by senior podcast producer Teresa Carey and managing editor Querida Anderson. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

To Listen to More Episodes from The Top Line